Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: IBIS past client WZE/ Lamberts
4
Aug 18, 2008 12:37AM

Aug 18, 2008 04:48AM

Aug 18, 2008 02:38PM

I'm not advocating PTSC will seek financing. I was simply replying based on the example (WZE) that was given and don't necessarily put a lot of stock right now in what Ibis can due for us.......

Now looking at the PTSC landscape, we are close to completing an acquisition that may wipe out all of our treasury shares at this SP point in time (and those shares having cost us far more than buying them on the open market). There may be another M&A deal in the works, and while there is cash, a portion of it may be tied up. We have no guarantee about the flow of TPL cash and the results from the USTPO. Ibis has a history of raising cash through secondaries and warrants. So how else are you going to develop a relationship with institutional investors when we provide no projections or forward guidance and no contract announcements with figures and then raise the SP to move off the OTC?........

Just my observations.......

Regards......





Share
New Message
Please login to post a reply